Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecut...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504321/
https://www.ncbi.nlm.nih.gov/pubmed/28639410
http://dx.doi.org/10.1002/cam4.1104

Ejemplares similares

Ejemplares similares